Wu Tong, Warren Linda J
Department of Radiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Dr. Linda Warren and Associates, Vancouver, British Columbia, Canada.
Can Assoc Radiol J. 2022 Feb;73(1):101-106. doi: 10.1177/08465371211011707. Epub 2021 Jun 16.
We evaluated the contribution to cancer detection of supplemental breast ultrasound screening in women with dense breasts based on a single center experience by comparing our results with similar programs elsewhere.
We performed a retrospective review of handheld sonographer-performed screening ultrasound exams at our academic breast imaging center, from January 1st to December 31st, 2019. Breast density, breast cancer risk factors, BI-RADS assessment, and lesion pathology were reviewed and tallied, followed by derivation of the biopsy rate, breast cancer detection rate, PPV3 and average tumor size. These values were compared to published results of breast screening programs elsewhere.
695 screening breast ultrasounds for women with dense breasts and negative mammograms were performed in 2019. The biopsy rate was 1.3%, breast cancer detection rate was 7 in 1000, PPV3 was 42%, and the average tumor size was 9.0 ± 1.4 mm.
The first-year data of the breast screening ultrasound program at our practice are promising, demonstrating comparable cancer detection rate, higher PPV3, and similar biopsy rate in those with dense breasts compared with similar programs elsewhere. Longitudinal analysis and larger sample size are required for validation. Comparison of incidence and prevalence screening data is also warranted to elucidate the true value of this program.
通过将我们的结果与其他地方的类似项目进行比较,基于单一中心的经验,我们评估了补充性乳腺超声筛查对致密型乳腺女性癌症检测的贡献。
我们对2019年1月1日至12月31日在我们学术性乳腺影像中心由超声检查技师进行的手持式筛查超声检查进行了回顾性研究。对乳腺密度、乳腺癌风险因素、BI-RADS评估和病变病理进行了审查和统计,随后得出活检率、乳腺癌检测率、PPV3和平均肿瘤大小。将这些值与其他地方乳腺筛查项目公布的结果进行比较。
2019年对695名乳腺致密且乳腺X线摄影阴性的女性进行了乳腺筛查超声检查。活检率为1.3%,乳腺癌检测率为千分之七,PPV3为42%,平均肿瘤大小为9.0±1.4毫米。
我们实践中乳腺筛查超声项目的第一年数据很有前景,与其他地方的类似项目相比,在致密型乳腺女性中显示出相当的癌症检测率、更高的PPV3和相似的活检率。需要进行纵向分析和更大样本量的研究来验证。还需要比较发病率和患病率筛查数据,以阐明该项目的真正价值。